MOTRIN CAPLET TABLET
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
05-08-2015
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
IBUPROFEN
Tillgänglig från:
MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC
ATC-kod:
M01AE01
INN (International namn):
IBUPROFEN
Dos:
200MG
Läkemedelsform:
TABLET
Sammansättning:
IBUPROFEN 200MG
Administreringssätt:
ORAL
Enheter i paketet:
24/50
Receptbelagda typ:
OTC
Terapiområde:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0108883004; AHFS:
Bemyndigande status:
CANCELLED POST MARKET
Tillstånd datum:
2016-01-22
Produktens egenskaper
PRODUCT MONOGRAPH
MOTRIN
®
200 mg
Ibuprofen Tablets USP, 200 mg
MOTRIN
®
Caplet
Ibuprofen Tablets USP, 200 mg
MOTRIN
®
Gelcaps
Ibuprofen Tablets USP, 200 mg
MOTRIN
®
300 mg
Ibuprofen Tablets USP, 300 mg
MOTRIN
®
400 mg
Ibuprofen Tablets USP, 400 mg
Non-Steroidal Anti-inflammatory Drug
Analgesic, Antipyretic Agent
McNeil Consumer Healthcare
Division of Johnson & Johnson Inc.
88 McNabb Street
Markham, Canada
L3R 5L2
Date of Preparation:
May 10, 2002
Date of Revision:
February 26, 2015
Control # 181377
_ _
_Page 2 of 41_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................11
DRUG INTERACTIONS
..................................................................................................15
DOSAGE AND ADMINISTRATION
..............................................................................17
OVERDOSAGE
................................................................................................................18
ACTION AND CLINICAL PHARMACOLOGY
............................................................19
STORAGE AND STABILITY
..........................................................................................21
SPECIAL HANDLING INSTRUCTIONS
.......................................................................21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
.........................................................
Läs hela dokumentet
